Skip to main content
Erschienen in: Pathology & Oncology Research 2/2011

01.06.2011 | Research

PHOSPHO-STAT5 Expression is Associated with Poor Prognosis of Human Colonic Adenocarcinoma

verfasst von: Yin-Ling Mao, Zhi-Wei Li, Chang-Jie Lou, Da Pang, Yan-Qiao Zhang

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

The signal transducer and activator of transcription-5 (STAT5) protein has been shown to play an important role in tumor progression through stimulating cell proliferation and preventing apoptosis. STAT5 activation has been observed in a variety of human tumors and cancer cell lines. However, it is not clear how activated STAT5 is expressed in colon cancer. In this study, we aimed to investigate phospho-STAT5 (activated form of STAT5) expression and its relationship with the clinicopathological factors and overall survival of patients with colonic adenocarcinoma. A total of 121 histological samples were selected for this study. Immunohistochemistry was used to detect the expression of phospho-STAT5. Analysis of the immunohistochemical staining was based on the proportion of stained cells in the field: positive, >15% stained cells, and negative, <15% stained cells. Survival times were analyzed using the Kaplan-Meier method, and the differences between groups were assessed with the log-rank test. A multivariate Cox regression model was used for prognostic power analysis. Expression of phospho-STAT5 was observed in the cytoplasms of colonic adenocarcinoma cells. Univariate analysis showed that phospho-STAT5 immunoreactivity was correlated with the depth of tumor invasion (P-value = 0.009), tumor-node-metastasis (TNM) stage (P-value = 0.048) and shorter overall survival times (P-value = 0.026). Lymph node metastasis, distant metastasis and TNM stage were associated with shorter overall survival times (P-value range from 0.003- < 0.001). Multivariate analysis showed that only distant metastasis was an independent predictor of overall survival time (P-value = 0.016). Our findings first demonstrate that phospho-STAT5 is frequently present and active in colonic adenocarcinoma and related to poor prognosis.
Literatur
1.
Zurück zum Zitat Lievre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995PubMedCrossRef Lievre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995PubMedCrossRef
2.
Zurück zum Zitat Galizia G, Lieto E, Ferraraccio F et al (2004) Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 10:3490–3499PubMedCrossRef Galizia G, Lieto E, Ferraraccio F et al (2004) Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 10:3490–3499PubMedCrossRef
3.
Zurück zum Zitat Muto T, Kotake K, Koyama Y (2001) Colorectal cancer statistics in Japan: data from JSCCR registration, 1974–1993. Int J Clin Oncol 6:171–176PubMedCrossRef Muto T, Kotake K, Koyama Y (2001) Colorectal cancer statistics in Japan: data from JSCCR registration, 1974–1993. Int J Clin Oncol 6:171–176PubMedCrossRef
4.
Zurück zum Zitat Newland RC, Dent OF, Lyttle MN et al (1994) Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer 73:2076–2082PubMedCrossRef Newland RC, Dent OF, Lyttle MN et al (1994) Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer 73:2076–2082PubMedCrossRef
5.
Zurück zum Zitat Guba M, Seeliger H, Kleespies A et al (2004) Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis 19:510–517PubMedCrossRef Guba M, Seeliger H, Kleespies A et al (2004) Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis 19:510–517PubMedCrossRef
6.
Zurück zum Zitat Kusaba T, Nakayama T, Yamazumi K et al (2006) Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15:1445–1451PubMed Kusaba T, Nakayama T, Yamazumi K et al (2006) Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15:1445–1451PubMed
7.
Zurück zum Zitat Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8:945–954PubMed Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8:945–954PubMed
8.
Zurück zum Zitat Calo V, Migliavacca M, Bazan V et al (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197:157–168PubMedCrossRef Calo V, Migliavacca M, Bazan V et al (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197:157–168PubMedCrossRef
10.
Zurück zum Zitat Ramana CV, Chatterjee-Kishore M, Nguyen H et al (2000) Complex roles of Stat1 in regulating gene expression. Oncogene 19:2619–2627PubMedCrossRef Ramana CV, Chatterjee-Kishore M, Nguyen H et al (2000) Complex roles of Stat1 in regulating gene expression. Oncogene 19:2619–2627PubMedCrossRef
11.
Zurück zum Zitat Corvinus FM, Orth C, Moriggl R et al (2005) Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 7:545–555PubMedCrossRef Corvinus FM, Orth C, Moriggl R et al (2005) Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 7:545–555PubMedCrossRef
12.
Zurück zum Zitat Gong W, Wang L, Yao JC et al (2005) Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 11:1386–1393PubMedCrossRef Gong W, Wang L, Yao JC et al (2005) Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 11:1386–1393PubMedCrossRef
13.
Zurück zum Zitat Wei D, Le X, Zheng L et al (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22:319–329PubMedCrossRef Wei D, Le X, Zheng L et al (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22:319–329PubMedCrossRef
14.
Zurück zum Zitat Coffer PJ, Koenderman L, de Groot RP (2000) The role of STATs in myeloid differentiation and leukemia. Oncogene 19:2511–2522PubMedCrossRef Coffer PJ, Koenderman L, de Groot RP (2000) The role of STATs in myeloid differentiation and leukemia. Oncogene 19:2511–2522PubMedCrossRef
15.
Zurück zum Zitat Li H, Zhang Y, Glass A et al (2005) Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 11:5863–5868PubMedCrossRef Li H, Zhang Y, Glass A et al (2005) Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 11:5863–5868PubMedCrossRef
16.
Zurück zum Zitat Li H, Ahonen TJ, Alanen K et al (2004) Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 64:4774–4782PubMedCrossRef Li H, Ahonen TJ, Alanen K et al (2004) Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 64:4774–4782PubMedCrossRef
17.
Zurück zum Zitat Nevalainen MT, Xie J, Torhorst J et al (2004) Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22:2053–2060PubMedCrossRef Nevalainen MT, Xie J, Torhorst J et al (2004) Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22:2053–2060PubMedCrossRef
18.
Zurück zum Zitat Lee TK, Man K, Poon RT et al (2006) Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res 66:9948–9956PubMedCrossRef Lee TK, Man K, Poon RT et al (2006) Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res 66:9948–9956PubMedCrossRef
19.
Zurück zum Zitat Xiong H, Su WY, Liang QC et al (2009) Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells. Lab Invest 89:717–725PubMedCrossRef Xiong H, Su WY, Liang QC et al (2009) Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells. Lab Invest 89:717–725PubMedCrossRef
20.
Zurück zum Zitat O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425PubMedCrossRef O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425PubMedCrossRef
21.
Zurück zum Zitat Jass JR, Sobin LH, Watanabe H (1990) The World Health Organization’s histologic classification of gastrointestinal tumors. A commentary on the second edition. Cancer 66:2162–2167PubMedCrossRef Jass JR, Sobin LH, Watanabe H (1990) The World Health Organization’s histologic classification of gastrointestinal tumors. A commentary on the second edition. Cancer 66:2162–2167PubMedCrossRef
22.
Zurück zum Zitat Hsiao JR, Jin YT, Tsai ST et al (2003) Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 89:344–349PubMedCrossRef Hsiao JR, Jin YT, Tsai ST et al (2003) Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 89:344–349PubMedCrossRef
23.
Zurück zum Zitat Ahonen TJ, Xie J, LeBaron MJ et al (2003) Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 278:27287–27292PubMedCrossRef Ahonen TJ, Xie J, LeBaron MJ et al (2003) Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 278:27287–27292PubMedCrossRef
24.
Zurück zum Zitat Ren S, Cai HR, Li M et al (2002) Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 21:4335–4339PubMedCrossRef Ren S, Cai HR, Li M et al (2002) Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 21:4335–4339PubMedCrossRef
25.
Zurück zum Zitat Cotarla I, Ren S, Zhang Y et al (2004) Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108:665–671PubMedCrossRef Cotarla I, Ren S, Zhang Y et al (2004) Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108:665–671PubMedCrossRef
26.
Zurück zum Zitat Harir N, Boudot C, Friedbichler K et al (2008) Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood 112:2463–2473PubMedCrossRef Harir N, Boudot C, Friedbichler K et al (2008) Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood 112:2463–2473PubMedCrossRef
27.
Zurück zum Zitat Harir N, Pecquet C, Kerenyi M et al (2007) Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood 109:1678–1686PubMedCrossRef Harir N, Pecquet C, Kerenyi M et al (2007) Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood 109:1678–1686PubMedCrossRef
28.
Zurück zum Zitat Klampfer L (2008) The role of signal transducers and activators of transcription in colon cancer. Front Biosci 13:2888–2899PubMedCrossRef Klampfer L (2008) The role of signal transducers and activators of transcription in colon cancer. Front Biosci 13:2888–2899PubMedCrossRef
Metadaten
Titel
PHOSPHO-STAT5 Expression is Associated with Poor Prognosis of Human Colonic Adenocarcinoma
verfasst von
Yin-Ling Mao
Zhi-Wei Li
Chang-Jie Lou
Da Pang
Yan-Qiao Zhang
Publikationsdatum
01.06.2011
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2011
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-010-9321-3

Weitere Artikel der Ausgabe 2/2011

Pathology & Oncology Research 2/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.